1
|
Labbozzetta M, Barreca M, Spanò V, Raimondi MV, Poma P, Notarbartolo M, Barraja P, Montalbano A. Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line. Drug Dev Res 2022; 83:1331-1341. [PMID: 35749723 PMCID: PMC9540667 DOI: 10.1002/ddr.21962] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Revised: 04/01/2022] [Accepted: 04/22/2022] [Indexed: 01/22/2023]
Abstract
A series of [1,2]oxazolo[5,4‐e]isoindole derivatives was evaluated against HL‐60 cell line and its multidrug resistance (MDR) variant, HL‐60R, resistant to doxorubicin and to other P‐gp substrates by overexpressing the efflux pump. They displayed antiproliferative activities, with IC50 values ranging from 0.02 to 5.5 µM. In particular, the newly synthesized compound 4k produced synergistic effects in terms of cell growth inhibition and cell death induction either in combination with a Vinca alkaloid, Vinblastine, and a Taxane, Paclitaxel in HL‐60R cells. The study of the mechanism of action indicated that all compounds showed antimitotic activity through inhibition of tubulin polymerization. Thus, [1,2]oxazoles could represent a valuable tool to overcome MDR mechanism, confirming the potential use of this class of compounds.
Collapse
Affiliation(s)
- Manuela Labbozzetta
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Marilia Barreca
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Virginia Spanò
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Maria Valeria Raimondi
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Paola Poma
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Monica Notarbartolo
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Paola Barraja
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Alessandra Montalbano
- Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| |
Collapse
|
2
|
Shankaraiah N, Nekkanti S, Ommi O, P.S. LS. Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer. Curr Med Chem 2019; 26:7059-7080. [DOI: 10.2174/0929867325666180410110729] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 01/01/2018] [Accepted: 04/05/2018] [Indexed: 12/18/2022]
Abstract
:
The efficacy of successful cancer therapies is frequently hindered by the development of drug
resistance in the tumor. The term ‘drug resistance’ is used to illustrate the decreased effectiveness of a
drug in curing a disease or alleviating the symptoms of the patient. This phenomenon helps tumors to survive
the damage caused by a specific drug or group of drugs. In this context, studying the mechanisms of
drug resistance and applying this information to design customized treatment regimens can improve therapeutic
efficacy as well as the curative outcome. Over the years, numerous Multidrug Resistance (MDR)
mechanisms have been recognized and tremendous effort has been put into developing agents to address
them. The integration of data emerging from the elucidation of molecular and biochemical pathways and
specific tumor-associated factors has shown tremendous promise within the oncology community for improving
patient outcomes. In this review, we provide an overview of the utility of these molecular and biochemical
signaling processes as well as tumor-associated factors associated with MDR, for the rational
selection of cancer treatment strategies.
Collapse
Affiliation(s)
- Nagula Shankaraiah
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India
| | - Shalini Nekkanti
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India
| | - Ojaswitha Ommi
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India
| | - Lakshmi Soukya P.S.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India
| |
Collapse
|
3
|
Methyl 5-[(1H-indol-3-yl)selanyl]-1H-benzoimidazol-2-ylcarbamate (M-24), a novel tubulin inhibitor, causes G2/M arrest and cell apoptosis by disrupting tubulin polymerization in human cervical and breast cancer cells. Toxicol In Vitro 2017; 42:139-149. [DOI: 10.1016/j.tiv.2017.04.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 12/02/2016] [Accepted: 04/12/2017] [Indexed: 11/20/2022]
|
4
|
Zuo D, Pang L, Shen J, Guan Q, Bai Z, Zhang H, Li Y, Lu G, Zhang W, Wu Y. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest. Int J Oncol 2017; 50:2069-2078. [PMID: 28440465 DOI: 10.3892/ijo.2017.3963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 03/13/2017] [Indexed: 11/06/2022] Open
Abstract
In the current study, we synthesized a series of new compounds targeting tubulin and tested their anti-proliferative activities. Among these new synthetic com-pounds, 5-(furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f) exhibited significant anti-proliferative activity against different human cancer cell lines including human gastric adenocarcinoma SGC-7901, human non-small cell lung cancer A549, and human fibrosarcoma HT-1080. As a result, 6f was selected to further test the sensitivity to different cancer cell lines including human cervical cancer cell line HeLa, human breast cancer cell line MCF-7, non-small cell lung cancer cell line A549, human liver carcinoma cell line HepG-2, human oral squamous cell carcinoma cell lines KB, SGC-7901 and HT-1080. Among these cell lines, HT-1080 and HeLa are the most sensitive. Therefore, HT-1080 was selected to further explore the properties of anti-proliferative activity and the underlying mechanisms. Our data proved that 6f exhibited strong anti-proliferative effects against HT-1080 cells in a time- and dose-dependent manner. We showed that the growth inhibitory effect of 6f in HT-1080 cells was related with microtubule depolymerisation. Molecular docking studies revealed that 6f interacted and bound efficiently with the colchicine-binding site of tubulin. In addition, 6f treatment induced G2/M cell cycle arrest dose-dependently and subsequently induced cell apoptosis. Western blot study indicated that upregulation of cyclin B1 and p-cdc2 was related with G2/M arrest. 6f-induced cell apoptosis was associated with both mitochondrial and death receptor pathway. In conclusion, our data showed that 6f, among the newly synthetic compounds, exhibited highest anti-proliferative activity by disrupting the microtubule polymerisation, causing G2/M arrest and subsequently inducing cell apoptosis in HT-1080 cells. Hence, 6f is a promising microtubule depolymerising agent for the treatment of various cancers especially human fibrosarcoma.
Collapse
Affiliation(s)
- Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Lili Pang
- Department of Clinical Pharmacy, The Sixth People's Hospital of Chengdu, Chengdu, Sichuan 610051, P.R. China
| | - Jiwei Shen
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Qi Guan
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Zhaoshi Bai
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Huijuan Zhang
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Yao Li
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Guodong Lu
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Weige Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Yingliang Wu
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| |
Collapse
|
5
|
|
6
|
Qian Y, Liu D, Cao S, Tao Y, Wei D, Li W, Li G, Pan X, Lei D. Upregulation of the long noncoding RNA UCA1 affects the proliferation, invasion, and survival of hypopharyngeal carcinoma. Mol Cancer 2017; 16:68. [PMID: 28327194 PMCID: PMC5361721 DOI: 10.1186/s12943-017-0635-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 03/08/2017] [Indexed: 11/10/2022] Open
Abstract
Background Several long noncoding RNAs (lncRNAs) are involved in oncogenesis. Methods and Results Our microarray analysis showed that numerous lncRNAs are dysregulated in hypopharyngeal squamous cell carcinoma (HSCC) tumor tissues as compared with normal tissues. Among those lncRNAs, urothelial carcinoma-associated 1 (UCA1) has been found to have an oncogenic role in HSCC. We confirmed the upregulation of UCA1 in HSCC by assessing its expression levels in a cohort of 53 patient tumors and paired non-tumor samples. In addition, we found that high UCA1 expression was significantly associated with advanced T category, late clinical stage, greater lymphatic invasion, and worse prognosis. Furthermore, in vitro experiments demonstrated that UCA1 functioned as an oncogene by promoting the proliferation and invasion and preventing the apoptosis of HSCC cells. Conclusions Taken together, our findings for the first time identify the role of UCA1 as a tumor promoter and a pro-metastatic factor in HSCC, demonstrating that UCA1 is a potential prognostic biomarker and therapeutic target in HSCC.
Collapse
Affiliation(s)
- Ye Qian
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China
| | - Dayu Liu
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China
| | - Shengda Cao
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China
| | - Ye Tao
- Department of Otolaryngology & Head and Neck Surgery, 2nd Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Dongmin Wei
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China
| | - Wenming Li
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China
| | - Guojun Li
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.,Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Xinliang Pan
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China.
| | - Dapeng Lei
- Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West Wenhua Road, Jinan, Shandong, 250012, People's Republic of China.
| |
Collapse
|